Full Logo No Tagline Color
Donations
Donations
SAKK 16/18

Immunotherapy and radiotherapy in stage III non-small cell lung cancer

Coordinating Investigator

  • Laetitia Mauti

    Leitende Ärztin

Patients with stage III non-small cell lung cancer may be treated with curative intent. However, there is a high recurrence rate. The SAKK 16/18 trial seeks to establish whether the prognosis can be improved by immunotherapy and radiotherapy given in addition to the standard treatment.

A number of therapeutic options are available for patients with stage III non-small cell lung cancer (locally advanced NSCLC). In Switzerland, the standard treatment consists of neoadjuvant chemotherapy with subsequent tumor surgery. Although this treatment is given with curative intent, most patients suffer recurrence of the disease. As a result, the 5-year survival rate is only 12–41%.

Does the addition of immunotherapy and radiotherapy improve the prognosis?

The SAKK 16/18 trial seeks to establish whether the prognosis can be improved when patients additionally receive preoperative immunotherapy with the anti-PD-L1 antibody durvalumab in combination with radiotherapy. Immunotherapy and radiotherapy are given in addition to the standard treatment (neoadjuvant chemotherapy plus surgery). 90 patients with stage III (locally advanced) NSCLC (N2) can join the trial.

Lifelong follow-up

After the trial therapy there will be a follow-up period in which regular check-ups are performed. These will take place:

  • every three months in the first two years,
  • every six months in the next three years,
  • and once a year as of the sixth year after completion of treatment (lifelong).

Further Studies: Lung cancer

SAKK LuCa 2

Registry and study of EGFR-mutated NSCLC

salVage

Phase III randomized controlled trial comparing maintenance systemic therapy alone with systemic therapy plus local ablative treatment for patients with advanced stage IV non-small cell lung cancer

ETOP CHESS

A multicentre single arm phase II trial assessing the efficacy of radical immunotherapy and chemotherapy, stereotactic radiotherapy and surgery in patients with synchronous oligo-metastatic NSCLC

Study 22615

ACHILES

ACHILES Does immunotherapy improve survival in patients with small cell lung cancer with limited disease who have received chemotherapy and radiotherapy?

ETOP ADOPT

An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC

ETOP RAISE

A single-arm phase II trial of the addition of niraparib to anti-PD-L1 antibody maintenance in patients with SLFN11-positive, extensive-disease small cell lung cancer. RAISE: Niraparib added to anti-PD-L1 antibody maintenance in SLFN11-positive, extensive-disease SCLC

SAKK 15/19

Study SAKK 15/19 Radiation of lung tumor and maintenance therapy with durvalumab following treatment with chemotherapy and durvalumab in patients with advanced small cell lung cancer

SAKK 19/17

Study SAKK 19/17 - Durvalumab in patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC) and inadequate general condition - A multicenter single-arm phase II study.